Analyzing tear samples to identify eye surface conditions

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to analyze tear samples from patients with various ocular surface pathologies, including dry eye syndrome and allergic conjunctivitis, using mass spectrometry. The goal is to establish a 'lacrimal fingerprint' for these conditions and create a normative baseline for comparison. Patients will have their tears collected via Schirmer strips during regular clinic visits at the ophthalmology department of the Centre Hospitalier de l'Université de Montréal. The collected samples will be sent to the Université du Québec à Montréal for detailed proteomic and metabolomic analysis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with healthy corneas or suffering from one of these pathologies:

Dry eye syndrome; Infectious keratitis and/or conjunctivitis; Mucous membrane pemphigoid; Allergic conjunctivitis.

Exclusion Criteria:

* Patients younger than 18 years old;
* Patients incapable of giving informed consent.

Where it's running

• Centre Hospitalier de l'Université de Montréal (CHUM)
  Montreal, Quebec, Canada Recruiting
• Université du Québec à Montréal (UQAM) - Department of Chemistry
  Montreal, Quebec, Canada Active not recruiting

Study contacts

• Principal investigator: Marie-Claude Robert, MD, M.Sc — Centre hospitalier de l'Université de Montréal (CHUM)
• Study coordinator: Marie-Claude Robert, MD, M.Sc
• Email: marie-claude.robert.2@umontreal.ca
• Phone: 514-890-8278

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cat-allergy eye allergy treatment with REGN-2Cat and study drugs in adults and kids

  This trial tests fel d 1 monoclonal antibodies (freneslerbart and mevonlerbart) alone or together to see if they reduce cat‑induced allergic conjunctivitis symptoms compared with placebo in adults and children.

  Recruiting at 2 sites Phase 3 Regeneron Pharmaceuticals · Long Beach, California and 1 other locations · NCT07675811

• Eye drops made from a child's own blood serum for dry eyes

  This will try eye drops made from each child's own blood serum to see if they help children under 18 with moderate-to-severe dry eye that hasn't improved with artificial tears.

  Recruiting The General Authority for Teaching Hospitals and Institutes · Cairo · NCT07295691

• TL-925 eye drops for allergic conjunctivitis

  This trial will test whether TL-925 eye drops relieve allergy-related eye redness and itching in adults with seasonal or perennial allergic conjunctivitis using a controlled allergen challenge.

  Recruiting Phase 2 Telios Pharma, Inc. · Smyrna, Tennessee · NCT07220408

• Intravenous ABBV-319 for adults with SLE or Sjögren's disease

  This trial will test whether two IV doses of ABBV-319 given 21 days apart are safe, reach expected blood levels, and might help adults with SLE or Sjögren's disease.

  Recruiting at 9 sites Phase 1 AbbVie · Avon Park, Florida and 10 other locations · NCT06977724

• Evaluating TL-925 for treating allergic conjunctivitis

  This study is testing if a new eye drop called TL-925 can help people with allergic conjunctivitis feel better compared to a placebo.

  Recruiting Phase 2 Telios Pharma, Inc. · Memphis, Tennessee · NCT06686472

• Assessing the burden of rare skin diseases

  This study is trying to understand how nine rare skin diseases affect the daily lives of patients and their families, including their emotional, social, and financial challenges.

  Recruiting at 6 sites Institut National de la Santé Et de la Recherche Médicale, France · Bobigny and 14 other locations · NCT05954416

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.